Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis

Mycoses

Volumn 54, Issue SUPPL. 1, 2011, Pages 1-6

  Karthaus, Meinolf ^a   Hentrich, Marcus ^b  

^a Klinikum Neuperlach   (Germany)

^b Klinikum Harlaching   (Germany)

Author keywords

Empirical antifungal therapy; Invasive fungal infection; Neutropenia; Prophylaxis of invasive fungal infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; GALACTOMANNAN; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ARTICLE; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDIASIS; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; EARLY DIAGNOSIS; FEBRILE NEUTROPENIA; FEVER; FUNGAL COLONIZATION; GRAFT VERSUS HOST REACTION; HUMAN; INVASIVE ASPERGILLOSIS; LUNG INFILTRATE; LYMPHOCYTOPENIA; MORTALITY; MUCOSA INFLAMMATION; NEUTROPENIA; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; RHINOSINUSITIS; RISK FACTOR; STEROID THERAPY; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; TREATMENT PLANNING; ZYGOMYCOSIS;

ANTIFUNGAL AGENTS; FEVER; FUNGI; HUMANS; MYCOSES; NEUTROPENIA;

EID: 78650133598     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01978.x     Document Type: Article

References (44)

1. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709.
2. Rex JH, Walsh TJ, Anaissie EA. Fungal infections in iatrogenically compromised hosts. Adv Intern Med 1998; 43: 321-71.
3. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78.
4. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
5. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101: 3365-72. Epub 2002 Aug 29.
6. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 322: 579-82.
7. Böhme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
8. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
9. Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-8.
10. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
11. Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 2007; 27: 1644-50.
12. Ullmann AJ, Cornely OA. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 2006; 19: 571-6.
13. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51.
14. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-52.
15. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-61.
16. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
17. Vehreschild JJ, Böhme A, Buchheidt D et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007; 55: 445-9.
18. Wingard JR, Carter SL, Walsh TJ et al. Results of a randomized, double-blind trial of fluconazole vs voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients. Blood 2007; 110: 55a-56a. Abstract 163.
19. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
20. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47. Erratum in: N Engl J Med 2007 Jul 26;357(4):428.
21. Ullmann AJ, Cornely OA, Burchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658-66.
22. Kohl V, Müller C, Cornely OA et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 2010; 54: 207-12.
23. Lebeaux D, Lanternier F, Elie C et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 2009; 53: 5224-9. Epub 2009 Sep 14.
24. Rickerts V, Böhme A, Just-Nübling G. Risk factor for invasive zygomycosis in patients with hematologic malignancies. Mycoses 2002; 45(Suppl. 1): 27-30.
25. Lass-Flörl C. Zygomycosis: conventional laboratory diagnosis. Clin Microbiol Infect 2009; 15(Suppl. 5): 60-65.
26. Trifilio SM, Bennett CL, Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-9.
27. Lekakis LJ, Lawson A, Prante J et al. Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. Biol Blood Marrow Transplant 2009; 15: 991-5.
28. Mousset S, Bug G, Heinz WJ, Tintelnot K, Rickerts V. Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation. Transpl Infect Dis 2010; 12: 261-264. Epub 2009 November 30.
29. Ananda-Rajah MR, Grigg A, Slavin MA. Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis. Mycopathologia 2008; 166: 83-86. Epub 2008 May 30.
30. Rieger C, Geiger S, Herold T, Nickenig C, Ostermann H. Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 2007; 26: 843-5.
31. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
32. Karthaus M. Voriconazole versus amphotericin B for invasive aspergillosis. N Engl J Med 2002; 347: 2080-1.
33. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-97.
34. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71. Epub 2004 Nov 9.
35. Viscoli C, Herbrecht R, Akan H et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64: 1274-81. Epub 2009 Oct 19.
36. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
37. Betts R, Glasmacher A, Maertens J et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006; 106: 466-73.
38. Kuse ER, Chetchotisakd P, Da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
39. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
40. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
41. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-49.
42. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Betsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641-9.
43. Maertens JA, Klont R, Masson C et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44: 1329-36.
44. Rickerts V, Böhme A, Viertel A, Behrendt G, Jacobi V, Tintelnot K, Just-Nübling G. Cluster of pulmonary infections caused by Cunninghamella bertholletiae in immunocompromised patients. Clin Infect Dis 2000; 31: 910-3.